SPMC J Health Care Serv. 2018;4(1):2 ARK: https://n2t.net/ark:/76951/jhcs74qyf9
1Misamis Oriental Provincial Hospital - Gingoog, Doña Graciana St, San Miguel, Gingoog City, Misamis Oriental, Philippines
2Agusan del Norte Provincial Hospital, Butuan City, Agusan del Norte, Philippines
3Department of Internal Medicine, Davao Regional Medical Center, Apokon, Tagum City, Philippines
4Bishop Joseph Regan Memorial Hospital, Christ the King Road, Tagum City, Davao del Norte, Philippines
5Medical Mission Group Hospital and Health Services Cooperative of Tagum, Department of Trade and Industry - Davao del Norte Field Office, Tagum City, Davao del Norte, Philippines
6Tagum Doctors Hospital Inc, National Highway, 54 Rabe Subdivision, Tagum City, Davao del Norte, Philippines
7Aquino Medical Specialists Hospital Inc, Mabini St, Tagum City, Davao del Norte, Philippines
Correspondence Arlyn Gaballo Awing, arlynawing@gmail.com
Article editors Emily Doliente-Gavarra, Jay Lord Canag
Received 5 July 2017
Accepted 4 April 2018
Cite as Awing AG, Llanos A. Clinical factors associated with hypomagnesemia among patients with cardiac conditions: cross-sectional study. SPMC J Health Care Serv. 2017;4(1):2. https://n2t.net/ark:/76951/jhcs74qyf9
Table 1 Clinical characteristics of patients | ||||
Characteristics | Total n=112 |
With Hypomagnesemia n=47 |
Without Hypomagnesemia n=65 |
p-value |
---|---|---|---|---|
Mean age ± SD, years | 60.72 ± 16.73 | 62.38 ± 17.69 | 59.52 ± 16.03 | 0.3715 |
Sex, frequency (%) | 0.9263 | |||
Male | 59 (52.68) | 25 (53.19) | 34 (52.31) | |
Female | 53 (47.32) | 22 (46.81) | 31 (47.69) | |
Cardiac diagnoses, frequency (%)* | ||||
Stable angina | 38 (33.93) | 19 (40.43) | 19 (29.23) | 0.2168 |
Unstable angina | 8 (7.14) | 2 (4.26) | 6 (9.23) | 0.4644† |
NSTEMI | 30 (26.79) | 14 (29.79) | 16 (24.62) | 0.5419 |
STEMI | 16 (14.29) | 6 (12.77) | 10 (15.38) | 0.6359 |
Congenital heart disease | 1 (0.89) | 0(0) | 1 (100.00) | 1.0000† |
Dilated cardiomyopathy | 10 (8.93) | 3 (6.38) | 7 (10.77) | 0.5158† |
Rheumatic heart disease | 5 (4.46) | 1 (2.13) | 4 (6.15) | 0.3966† |
Valvular heart disease | 3 (2.68) | 1 (2.13) | 2 (3.08) | 1.0000† |
Thyrotoxic heart disease | 7 (6.25) | 2 (4.26) | 5 (7.69) | 0.6970† |
Medical comorbidities, frequency (%)* | ||||
Heart failure | 71 (63.39) | 28 (59.57) | 43 (66.15) | 0.4757 |
Hypertension | 69 (61.61) | 32 (68.09) | 37 (56.92) | 0.2452 |
Diabetes mellitus | 25 (22.32) | 11 (23.40) | 14 (21.54) | 0.8150 |
Dyslipidemia | 9 (8.04) | 3 (6.38) | 6 (9.23) | 0.7319† |
COPD | 9 (8.04) | 7 (14.89) | 2 (3.08) | 0.0336†‡ |
Acute renal failure | 28 (25.00) | 13 (27.66) | 15 (23.08) | 0.5804 |
Chronic renal failure | 7 (6.25) | 5 (10.64) | 2 (3.08) | 0.1283† |
Stroke | 28 (25.00) | 17 (36.17) | 11 (16.92) | 0.0203† |
Medication, frequency (%)* | ||||
Digoxin | 7 (6.25) | 4 (8.51) | 3 (4.62) | 0.4505† |
Steroids | 5 (4.46) | 4 (8.51) | 1 (1.54) | 0.1594† |
Diuretics | 15 (13.39) | 11 (23.40) | 4 (6.15) | 0.0082†‡ |
Clinical events, frequency (%)* | ||||
Atrial fibrillation | 61 (54.46) | 31 (65.96) | 30 (46.15) | 0.0378‡ |
Ventricular tachycardia | 5 (4.46) | 1 (2.13) | 4 (6.15) | 0.3966† |
Died | 18 (16.07) | 5 (10.64) | 13 (20.00) | 0.1830 |
*One patient may have more than one cardiac diagnosis, medical comorbidity, medication, or clinical event. †Compared using Fisher’s exact test. ‡Significant at p<0.05. COPD—chronic obstructive pulmonary disease; NSTEMI—Non-ST-elevation myocardial infarction; STEMI—ST-elevation myocardial infarction. |
Table 2 Logistic regression analysis showing the association of selected clinical factors with hypomagnesemia | ||||
Clinical factors | Unadjusted | Adjusted* | ||
---|---|---|---|---|
Prevalence odds ratio (95% CI) n=112 |
p-value | Prevalence odds ratio (95% CI) n=112 |
p-value | |
Medical comorbidities | ||||
Hypertension | 1.61 (0.74 to 3.54) | 0.2321 | 1.26 (0.51 to 3.11) | 0.6120 |
Heart failure | 0.75 (0.35 to 1.64) | 0.4761 | 0.79 (0.32 to 1.91) | 0.5949 |
Diabetes mellitus | 1.11 (0.45 to 2.73) | 0.8142 | 0.94 (0.36 to 2.41) | 0.8903 |
Dyslipidemia | 0.67 (0.16 to 2.83) | 0.5863 | 0.64 (0.14 to 2.94) | 0.5646 |
COPD | 5.50 (1.09 to 27.76) | 0.0392† | 6.54 (1.03 to 41.66) | 0.0469† |
Acure renal failure | 1.27 (0.54 to 3.02) | 0.5809 | 1.34 (0.52 to 3.43) | 0.5450 |
Chronic renal failure | 3.75 (0.69 to 20.23) | 0.1244 | 3.18 (0.56 to 18.19) | 0.1933 |
Stroke | 2.78 (1.15 to 6.71) | 0.0227† | 2.48 (0.95 to 6.43) | 0.0624 |
Medications | ||||
Digoxin | 1.92 (0.41 to 9.03) | 0.4075 | 13.69 (0.91 to 207.11) | 0.0589 |
Steroids | 5.95 (0.64 to 55.1 0) | 0.1161 | 6.44 (0.54 to 76.91) | 0.1412 |
Diuretics | 4.66 (1.38 to 15.71) | 0.0132† | 4.92 (1.32 to 18.31) | 0.0175† |
Clinical events | ||||
Atrial fibrillation | 2.26 (1.04 to 4.91) | 0.0394† | 3.12 (1.22 to 7.96) | 0.0171† |
Ventricular tachycardia | 0.33 (0.04 to 3.07) | 0.3307 | 0.31 (0.03 to 3.31) | 0.3296 |
Death | 0.48 (0.16 to 1.44) | 0.1905 | 0.48 (0.15 to 1.57) | 0.2265 |
*For age, sex, and cardiac diagnosis †Significant at p<0.05. COPD—chronic obstructive pulmonary disease; NSTEMI—Non-ST-elevation myocardial infarction; STEMI—ST-elevation myocardial infarction. |
Acknowledgments
We would like to thank Ms Aileen Ceballos for her assistance in the implementation of this research, and Dr Dizza R Dujali for reviewing the protocol and final report of this research.
Ethics approval
This study was reviewed and approved by the Department of Health XI Cluster Ethics Review Committee (DOH XI CERC reference P16060701).
Reporting guideline used
STROBE Checklist (https://www.strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_combined.pdf)
Article source
Submitted
Peer review
External
Funding
Supported by personal funds of the authors
Competing interests
None declared
Access and license
This is an Open Access article licensed under the Creative Commons Attribution-NonCommercial 4.0 International License, which allows others to share and adapt the work, provided that derivative works bear appropriate citation to this original work and are not used for commercial purposes. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0/.
1. Rasmussen HS, McNair P, Gøransson L, Balsløv S, Larsen OG, Aurup. Magnesium deficiency in patients with ischemic heart disease with and without acute myocardial infarction uncovered by an intravenous loading test. Arch Intern Med. 1988;148(2):329-332.
2. Longo DL, Kasper DL, Fauci AS, Hauser SL, Jameson JL, Loscalzo J. Harrison’s principles of internal medicine. 19th ed. New York: Mcgraw Hill; 2015.
3. Ceremuzynski L, Van Hao N. Ventricular arrhythmias late after myocardial infarction are related to hypomagnesemia and magnesium loss: preliminary trial of corrective therapy. Clin Cardiol. 1993;16(6):493-6.
4. Khan AM, Lubitz SA, Sullivan LM, Sun JX, Levy D, Vasan RS et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circ Res. 2013;127(1):33-8.
5. Horner SM. Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality. Meta-analysis of magnesium in acute myocardial infarction. Circ Res. 1992;86(3):774-9.
6. Falco CN, Grupi C, Sosa E, Scanavacca M, Hachul D, Lara S et al. Successful improvement of frequency and symptoms of premature complexes after oral magnesium administration. Arq Bras Cardiol. 2012;98(6):480-7.
7. Volpe SL. Magnesium and the Athlete. Curr Sports Med Rep. 2015;14(4):279-83.
8. Wu J, Carter A. Magnesium: the forgotten electrolyte. Aust Prescr. 2007;30:102-5.
9. Roden DM. Magnesium treatment of ventricular arrhythmias. Am J Cardiol. 1989;63(14):43g-46g.
10. Zanoli L, Lentini P, Fatuzzo P. Digoxin and Hypermagnesuria. Nephron. 2018;138(2):89-91.
11. Abu-Amer N, Priel E, Karlish SJD, Farfel Z, Mayan H. Hypermagnesuria in Humans Following Acute Intravenous Administration of Digoxin. Nephron. 2018;138(2):113-118.
12. Young IS, Goh EM, McKillop UH, Stanford CF, Nicholls DP, Trimble ER. Magnesium status and digoxin toxicity. Br J Clin Pharmacol. 1991;32(6):717-21.
13. Raja Rao MP, Panduranga P, Sulaiman K, Al-Jufaili M. Digoxin toxicity with normal digoxin and serum potassium levels: beware of magnesium, the hidden malefactor. J Emerg Med. 2013;45(2):e31-4.
14. London B. Arrhythmias. In: Ginsburg G, Willard H. Genomic and personalized medicine. 2nd ed. New York: Elsevier; 2013. p. 1231-1249.
15. Gorenek B, Blomström-Lundqvist C, Terradellas JB, Camm AJ, Hindricks G, Huber K et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. EP Europace. 2018;16(11):1655-1673.
16. Betensky BP, Dixit S. Sudden cardiac death in patients with nonischemic cardiomyopathy. Indian Heart J. 2014;66(Suppl 1):S35-S45.
17. Tsymbaliuk BP, Unukovych D, Shvets, N, Dinets A. Cardiovascular complications secondary to graves’ disease: A prospective study from Ukraine. Plos One. 2015;10(3):e0122388.
18. Del Gobbo LC, Song Y, Poirier P, Dewailly E, Elin RJ, Egeland GM. Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes. Cardiovasc Diabetol. 2012; 11:23.
19. Madias JE, Sheth K, Mubashar A, Choudry, Berger DO, Madias NE. Admission serum magnesium level does not predict the hospital outcome of patients with acute myocardial infarction. Arch Intern Med. 1996;156(15):1701-1708.
20. Efstratiadis G, Sarigianni M, Gougourelas I. Hypomagnesemia and cardiovascular system. Hippokratia. 2006;10(4):147-52.
21. ilionis HJ, Alexandrides GE, Liberopoulos EN, Bairaktari ET, Goudevenos J, Elisaf MS. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail. 2002;4(2):167-73.
22. Davies DL, Fraser R. Do diuretics cause magnesium deficiency? Br J clin Pharmac. 1993;36: 1-10.
23. Gourgoulianis KI, Chatziparasidis G, Chatziefthimiou A, Molyvdas PA. Magnesium as a relaxing factor of airway smooth muscles. J Aerosol Med. 2001;14(3):301-7.
24. Azis, HS. (2005), Serum magnesium levels and accute exacerbation of chronic obstructive pulmonary disease: a retrospective study. Autum;35(4):423-7.
25. Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Ann Emerg Med. 2000;36(3):191-7.
26. Hughes R, Goldkorn A, Masoli M, Weatherall M, Burgess C, Beasley R. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Lancet. 2003;361(9375):2114-7.
27. Roy SR, Milgrom H. Managing outpatient asthma exacerbations. Curr Allergy Asthma Rep. 2003 Mar;3(2):179-89.
28. Nair RR, Nair P. Alteration of myocardial mechanics in marginal magnesium deficiency. Magnes Res. 2002 Dec;15(3-4):287-306.
29. Dresing TJ, Schweikert RA. Atrial fibrillation. In: Current clinical medicine. 2nd ed. Cleveland, OH: Saunders; 2010. p. 129-137.e1.
30. Onalan O, Crystal E, Daoulah A, Lau C, Crystal A, Lashevsky I. Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. Am J Cardiol. 2007;99(12):1726-32.
31. DeCarli C, Sprouse G, LaRosa JC. Serum magnesium levels in symptomatic atrial fibrillation and their relation to rhythm control by intravenous digoxin. Am J Cardiol. 1986 Apr 15;57(11):956-9.
32. Cojocaru IM, Cojocaru M, Burcin C, Atanasiu NA. Serum magnesium in patients with acute ischemic stroke. Rom J Intern Med. 2007; 45(3):269-73.
33. Rico M, Martinez-Rodriguez L, Larrosa-Campo D, Calleja S. Dilemma in the emergency setting: hypomagnesemia mimicking acute stroke. Int Med Case Rep J. 2016;9:145-8.
34. Yuan Z, Bowlin S, Einstadter D, Cebul RD, Conners AR Jr, Rimm AA. Atrial fibrillation as a risk factor for stroke: a retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health. 1998;88(3):395-400.
35. Hald EM, Rinde LB, Lochen ML, Mathiesen EB, Wilsgaard T, Njolstad I et al. Atrial fibrillation and cause-specific risks of pulmonary embolism and ischemic stroke. J Am Heart Assoc. 2018;7(3).
36. Cheungpasitporn W, Thongprayoon C, Qian Q. Dysmagnesemia in hospitalized patients: prevalence and prognostic importance. Mayo Clin Proc. 2015;90(8):1001-10.
37. Haider DG, Lindner G, Ahmad SS, Sauter T, Wolzt M, Leichtle AB et al. Hypermagnesemia is a strong independent risk factor for mortality in critically ill patients: Results from a cross-sectional study. Eur J Case Rep Intern Med. 2015;26(7):504-507.
38. Cai K, Luo Q, Dai Z, Zhu B, Fei J, Xue C et al. Hypomagnesemia is associated with increased mortality among peritoneal dialysis patients. PLoS One. 2016;11(3):e0152488.
39. Nakashima A, Ohkido I, Yokoyama K, Mafune A, Urashima M, Yokoo T. Proton pump inhibitor use and magnesium concentrations in hemodialysis patients: A cross-sectional study. PLoS One. 2015;10(11).
40. Yang X, Soohoo M, Streja E, Rivara MB, Obi Y, Adams SV et al. Serum magnesium levels and hospitalization and mortality in incident peritoneal dialysis patients: A cohort study. Am J Kidney Dis. 2016;68(4):619-27.
41. Charles BS, Menon I, Girish TS, Cherian AM. Hypomagnesemia in the ICU – Does Correction Matter? J Assoc Physicians India. 2016 Nov;64(11):15-19.
42. Behrouz R, Hafeez S, Mutgi SA, Zakaria A, Miller CM. Hypomagnesemia in Intracerebral Hemorrhage. World Neurosurg. 2015 Dec;84(6):1929-32.
43. Arinzon Z, Peisakh A, Schrire S, Berner YN. Prevalence of hypomagnesemia (HM) in a geriatric long-term care (LTC) setting. Arch Gerontol Geriatr. 2010; 51(1):36-40.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms: